跳转至内容
Merck
CN

SML2883

Sigma-Aldrich

Paquinimod

≥98% (HPLC), powder, immunomodulator

别名:

ABR 215757, ABR 25757, ABR-215757, ABR-25757, ABR215757, ABR25757, N,5-二乙基-1,2-二氢-4-羟基-1-甲基-2-氧基-N-苯基-3-喹啉甲酰胺, N-乙基-N-苯基-1,2-二氢-5-乙基-4-羟基-1-甲基-2-羟基喹啉-3-甲酰胺, N-乙基-N-苯基-5-乙基-1,2-二氢-4-羟基-1-甲基-2-羟基喹啉-3-甲酰胺

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C21H22N2O3
化学文摘社编号:
分子量:
350.41
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Paquinimod, ≥98% (HPLC)

质量水平

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

2-8°C

SMILES字符串

N1(c2c(c(ccc2)CC)C(=O)C(C1=O)C(=O)N(CC)c3ccccc3)C

InChI

1S/C21H22N2O3/c1-4-14-10-9-13-16-17(14)19(24)18(20(25)22(16)3)21(26)23(5-2)15-11-7-6-8-12-15/h6-13,18H,4-5H2,1-3H3

InChI key

RBHDLRDFJPBLNO-UHFFFAOYSA-N

生化/生理作用

Paquinimod (ABR-215757)是一种口服活性喹啉-3-甲酰胺(Q物质)类免疫调节剂,靶向S100A9(Calgranulin B;MRP14),并阻断其与晚期糖基化终产物受体(RAGE)和Toll样受体4的相互作用(IC50 = 26 μM & 23 μM对100 nM hS100A9, 分别结合固定化hRAGE & hTLR4/MD2)。Paquinimod在自身免疫性/炎症性疾病的小鼠模型中证明了体内疗效,包括肝纤维化、胶原诱导的骨关节炎、腹膜炎、EAE、1型糖尿病、狼疮(0.04-25 mg/kg/day p.o)和动脉粥样硬化(10 mg/kg i.p.)。
口服活性S100A9(Calgranulin B;MRP14)阻滞剂在自身免疫性疾病的小鼠模型中具有体内疗效

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

R F Schelbergen et al.
Annals of the rheumatic diseases, 74(12), 2254-2258 (2015-05-15)
Alarmins S100A8/A9 regulate pathology in experimental osteoarthritis (OA). Paquinimod is an immunomodulatory compound preventing S100A9 binding to TLR-4. We investigated the effect of paquinimod on experimental OA and human OA synovium. Two OA mouse models differing in level of synovial
Per Björk et al.
PLoS biology, 7(4), e97-e97 (2009-05-01)
Despite more than 25 years of research, the molecular targets of quinoline-3-carboxamides have been elusive although these compounds are currently in Phase II and III development for treatment of autoimmune/inflammatory diseases in humans. Using photoaffinity cross-linking of a radioactively labelled
Christina Wache et al.
The Journal of infectious diseases, 212(2), 247-257 (2015-01-22)
Neutrophilic inflammation often persists for days despite effective antibiotic treatment and contributes to brain damage in bacterial meningitis. We propose here that myeloid-related protein 14 (MRP14), an abundant cytosolic protein in myeloid cells, acts as an endogenous danger signal, driving
Sofia Helmersson et al.
The American journal of pathology, 182(5), 1671-1680 (2013-03-20)
Quinoline-3-carboxamide compounds (Q compounds) have demonstrated efficacy in treating autoimmune disease in both humans and mice. However, the mode of action of these compounds is poorly understood. Here, we show that preventive treatment with the Q compound paquinimod (ABR-215757) during
Michael J Kraakman et al.
The Journal of clinical investigation, 127(6), 2133-2147 (2017-05-16)
Platelets play a critical role in atherogenesis and thrombosis-mediated myocardial ischemia, processes that are accelerated in diabetes. Whether hyperglycemia promotes platelet production and whether enhanced platelet production contributes to enhanced atherothrombosis remains unknown. Here we found that in response to

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持